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Abstract
The parainfluenza viruses (PIVs) are highly contagious respiratory paramyxoviruses and a leading cause of lower respiratory
tract (LRT) disease. Since no vaccines or antivirals exist, non-pharmaceutical interventions are the only means of control for
these pathogens. Here we used bioluminescence imaging to visualize the spatial and temporal progression of murine PIV1
(Sendai virus) infection in living mice after intranasal inoculation or exposure by contact. A non-attenuated luciferase
reporter virus (rSeV-luc(M-F*)) that expressed high levels of luciferase yet was phenotypically similar to wild-type Sendai
virus in vitro and in vivo was generated to allow visualization. After direct intranasal inoculation, we unexpectedly observed
that the upper respiratory tract (URT) and trachea supported robust infection under conditions that result in little infection
or pathology in the lungs including a low inoculum of virus, an attenuated virus, and strains of mice genetically resistant to
lung infection. The high permissivity of the URT and trachea to infection resulted in 100% transmission to naı ¨ve contact
recipients, even after low-dose (70 PFU) inoculation of genetically resistant BALB/c donor mice. The timing of transmission
was consistent with the timing of high viral titers in the URT and trachea of donor animals but was independent of the levels
of infection in the lungs of donors. The data therefore reveals a disconnect between transmissibility, which is associated
with infection in the URT, and pathogenesis, which arises from infection in the lungs and the immune response. Natural
infection after transmission was universally robust in the URT and trachea yet limited in the lungs, inducing protective
immunity without weight loss even in genetically susceptible 129/SvJ mice. Overall, these results reveal a dichotomy
between PIV infection in the URT and trachea versus the lungs and define a new model for studies of pathogenesis,
development of live virus vaccines, and testing of antiviral therapies.
Citation: Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, et al. (2011) Illumination of Parainfluenza Virus Infection and Transmission in Living Animals
Reveals a Tissue-Specific Dichotomy. PLoS Pathog 7(7): e1002134. doi:10.1371/journal.ppat.1002134
Editor: Ron A. M. Fouchier, Erasmus Medical Center, Netherlands
Received February 11, 2011; Accepted May 7, 2011; Published July 7, 2011
Copyright:  2011 Burke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants R01AI083370 and R56AI083370 by the National Institute for Allergy and Infectious Diseases. This work was also
supported by the American Lebanese Syrian Associated Charities and the Children’s Infection Defense Center at St. Jude Children’s Research Hospital. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: charles.russell@stjude.org
. These authors contributed equally to this work.
Introduction
The parainfluenza viruses (PIVs) are non-segmented, negative-
strand RNA viruses of the family Paramyxoviridae. The paramyxo-
viruses include not only the PIVs but also a number of other
important human pathogens transmitted via the respiratory route
such as human respiratory syncytial virus (HRSV), metapneumo-
virus, measles virus, and mumps virus [1,2]. The human PIVs
(HPIVs) consist of four serotypes (HPIV1-4), are a common cause
of upper respiratory tract (URT) infections, and are a leading
cause of lower respiratory tract (LRT) disease in infants and
children [3]. The HPIVs are efficiently transmitted by direct
contact and exposure to nasopharyngeal secretions [4], and nearly
all children are infected with HPIV3 by age 2 and with HPIV1
and HPIV2 by age 5 [5,6]. No licensed anti-PIV vaccines or drugs
are available, and therefore non-pharmaceutical interventions are
currently the only means of control. In view of these facts, an
understanding of how PIV infection spreads within the respiratory
tract, promotes pathogenesis, elicits immunity, and is transmitted
to naı ¨ve hosts would greatly advance the development of novel
vaccines and therapeutics.
Experimental studies of HPIV infection in tissue culture and
animal models have helped reveal basic replication mechanisms
and evaluate preclinical vaccine candidates [7–9]. However,
knowledge about the spread of PIV infection in individual, living
animals that are fully susceptible to PIV-associated disease would
allow more thorough investigations of PIV virus-host interactions
and transmission. Mice are poorly permissive to infection by the
HPIVs, and HPIV infection in cotton rats, hamsters, guinea pigs,
and ferrets is usually asymptomatic with minimal or undetectable
pathology [1]. As a result, a number of studies have used Sendai
virus (SeV) infection of mice as a model to investigate pathogenesis
in an experimental setting [10,11]. SeV is the murine counterpart
of HPIV1, the leading cause of laryngotracheobronchitis (pediatric
croup) [12]. SeV and HPIV1 have 78% amino-acid sequence
identity [13], elicit cross-protective immunity [14–16], and have
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shows promise as a Jennerian vaccine for HPIV1 [17] and as a
vaccine vector for HRSV, HPIV3, and HPIV2 [18–20].
Although SeV and the HPIVs were first isolated in the 1950s
and have been studied for more than 50 years [1], fundamental
aspects of PIV infection and immunity that remain unknown are
directly relevant to our understanding of pathogenesis and
transmission. For example, the spatial and temporal spread of
natural infection in the respiratory tract after SeV transmission
remains poorly understood because of the ambiguous results
(marked inter-animal variability and error) of classical experiments
measuring virus titers in sacrificed mice [21,22]. It is also unknown
how HPIV and SeV infection after transmission often results in
immunity without causing severe pathology. The contribution of
LRT infection to transmission is unknown. Finally, while infection
of the lungs and the concomitant immune response are clearly
associated with disease severity [1,11,23,24], many questions
remain about the contribution of infection in the URT and
trachea to clinical outcome and protective immunity [25,26]. For
example, we are unaware of any reports of studies investigating the
effect of the dose of virus inoculum, the replicative fitness of the
virus, or the genetic susceptibility of the host on the growth and
clearance of SeV in the URT and trachea.
To measure the dynamics of PIV infection in living animals, we
generated three luciferase-expressing SeVs that allow non-invasive
in vivo bioluminescence imaging in mice. Analogous systems have
previously been reported for DNA and positive-strand RNA
viruses [27] but have been elusive for negative-strand RNA
viruses, largely due to virus attenuation [28] or genetic instability
resulting from reporter gene insertion [29]. We considered SeV an
ideal candidate for non-invasive imaging because (i) foreign-gene
expression by paramyxovirus vectors is usually genetically stable
[30], (ii) in vivo imaging of a non-replicating SeV in intact mice has
been successfully demonstrated [31] and (iii) the match of SeV and
the murine host allows pathogenesis studies [11]. The reporter
virus rSeV-luc(M-F*) described here was found to express high
levels of luciferase yet replicate and promote disease in mice
similar to wild-type (WT) virus. We imaged the dynamics of SeV
infection in living, intact mice after direct inoculation and after
contact transmission, varying both the virus dose and mouse
strain. Unexpectedly, we observed a dichotomous tissue tropism in
which the URT and trachea supported robust virus growth,
efficient transmission, and protective immunity even under
conditions that resulted in little infection in the lungs.
Results
In vitro properties of luciferase-expressing viruses
To develop a model in which PIV infection could be visualized
non-invasively in living, intact mice, we generated three
recombinant Sendai viruses (rSeVs) in which a firefly luciferase
reporter gene was inserted into the P-M, M-F, and F-HN gene
junctions, respectively, of SeV (Figure 1A, Figure S1). Insertion of
the firefly luciferase gene and gene junction into the SeV genome
was expected to unacceptably decrease downstream viral gene
expression and, consequently, virus replication [32]. To generate a
luciferase-expressing SeV expected to suffer little or no attenua-
tion, the rSeV-luc(M-F*) virus was constructed to contain both the
luciferase reporter gene and a more efficient transcription start
sequence AGGGTGAAAG upstream of the F gene (Figure S1).
Therefore, the attenuating effects of reporter gene insertion could
be counteracted by optimization of the naturally inefficient gene
start sequence upstream of the F gene [33]. For the rSeV-luc(P-M)
and rSeV-luc(F-HN) constructs, in which the luciferase gene was
inserted into the P-M and F-HN gene junctions, respectively, the
natural transcription start sequence upstream of the F gene was left
intact (Figure S1).
Multiple-step growth curves were measured at 33uC and 37uC
in LLC-MK2 cells that had been infected at a multiplicity of
infection (MOI) of 0.01 PFU/cell (Figure 1B). Titers of rSeV-
luc(M-F*) and rSeV-luc(F-HN) were similar at both temperatures
and similar to SeV WT, showing that these two luciferase-
expressing viruses were not substantially attenuated or tempera-
ture restricted. In contrast, the rSeV-luc(P-M) virus showed
reduced growth kinetics at 33uC and grew even more slowly at
37uC. To compare luciferase reporter gene expression by the
recombinant SeVs, we measured in vitro luciferase activity in LLC-
MK2 cell lysates (MOI 5 PFU/cell) (Figure 1C). Upstream
insertion of luciferase in rSeV-luc(P-M) resulted in greater
luciferase activity than did downstream insertion in rSeV-luc(F-
HN), consistent with the results of previous studies of SeVs using
secreted alkaline phosphatase as the reporter gene [32]. Luciferase
expression by rSeV-luc(M-F*) exceeded that of rSeV-luc(P-M)
within 6 h post-infection (p.i.), showing that the enhanced gene
start sequence engineered into the M-F* virus (Figure S1)
increased reporter-gene transcription at later time points, perhaps
due to greater downstream transcription of the L polymerase gene.
To determine how the reporter gene insertions might have altered
SeV protein expression, LLC-MK2 cells were infected at an MOI
of 5 PFU/cell and lysates were subjected to radioimmunoprecip-
itation and SDS-PAGE analysis. Low levels of expression of the M,
F, HN and presumably L proteins by the rSeV-luc(P-M) virus
(Figure S2A) most likely contributed to the attenuation of this
virus. Viral protein expression by rSeV-luc(M-F*) and rSeV-luc(F-
HN) was sufficient to generate virions with WT-like compositions
(Figure S2C), consistent with the in vitro growth of these two
reporter viruses to levels similar to that of WT virus (Figure 1B).
Virulence of the luciferase-expressing viruses
An ideal luciferase-reporter virus for non-invasive biolumines-
cence imaging and pathogenesis studies would express high levels
of luciferase without altering virus replication and disease severity.
Author Summary
Human parainfluenza viruses (HPIVs) are a leading cause of
pediatric hospitalization for lower respiratory tract infec-
tion, yet it is unknown why primary infection typically
induces immunity without causing severe pathology. To
study the determinants of PIV spread within the respira-
tory tracts of living animals, we developed a model for
non-invasive imaging of living mice infected with Sendai
virus, the murine counterpart of HPIV1. This system
allowed us to measure the temporal and spatial dynamics
of paramyxovirus infection throughout the respiratory
tracts of living animals after direct inoculation or
transmission. We found that the upper respiratory tract
and trachea were highly permissive to infection, even
under conditions that limit lower respiratory infection and
pathogenesis. The timing of transmission coincided with
high virus growth in the upper respiratory tracts and
trachea of donor mice independent of the extent of
infection in the lungs. After transmission, infection spread
preferentially in the upper respiratory tract and trachea,
inducing protective immunity without weight loss. Our
work reveals a disconnect between Sendai virus transmis-
sibility and pathogenicity, and the experimental model
developed here will be instrumental in studying PIV
pathogenesis.
PIV Infection and Transmission in Living Mice
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mice were anesthetized with isoflurane and inoculated intranasally
with 30 ml containing 7,000 PFU of virus. This method of
inoculation delivers ,1/3 of the volume to the nasopharynx and
,1/2 to the lungs [34]. Infection with SeV WT, rSeV-luc(M-F*),
and rSeV-luc(F-HN) resulted in a mean weight loss of ,25% and
mean mortality rates of 80% (Figure 1D,E). Thus, these two
luciferase-expressing viruses remained fully virulent at a dose of
7,000 PFU. In contrast, 129/SvJ mice inoculated with 7,000 PFU
of the attenuated rSeV-luc(P-M) virus experienced only 12%
weight loss and no mortality. All mice inoculated with 70,000 or
700,000 PFU of rSeV-luc(P-M) also survived (data not shown),
further demonstrating that the attenuated rSeV-luc(P-M) virus is
avirulent.
Acute viral pneumonia by SeV induces high levels of
lymphocyte infiltration that show a peak in bronchoalveolar
lavage fluid (BALF) at ,10 d p.i. [35]. To compare lymphocyte
influx caused by the luciferase-expressing viruses and WT virus,
we sacrificed 129/SvJ mice that had been infected with 7,000 PFU
at 10 d p.i. and collected BALF. Similarly large total numbers of
lymphocytes, CD4+ T-lymphocytes, and CD8+ T-lymphocytes
were detected in BALF after infection with WT, rSeV-luc(M-F*),
or rSeV-luc(F-HN) virus (Figure 1F; Figure S3A–B), whereas mice
inoculated with the attenuated rSeV-luc(P-M) had total lympho-
cyte counts only 10% as high. To determine the extents to which
the reporter viruses elicited SeV- or luciferase-binding antibodies,
ELISA assays were performed on sera collected at 10 d p.i. The
anti-SeV antibody titers elicited by all three rSeVs were similar to
that induced by WT virus (Figure 1G). The three reporter viruses
also induced similar anti-luciferase antibody titers (Figure S3C).
Thus, despite being attenuated and avirulent, rSeV-luc(P-M)
elicited a robust antibody response. rSeV-luc(M-F*), which
induced WT-like morbidity and mortality while expressing high
levels of luciferase, was identified as the best suited surrogate for
WT virus for use in subsequent bioluminescence imaging
experiments.
Dynamics of infection in living animals
In studies to determine whether non-invasive bioluminescence
accurately reflected in vivo infection, 129/SvJ mice were intranasally
inoculated with 7,000 PFU, imaged with a Xenogen IVIS
instrument, and immediately euthanized. Respiratory tissues were
promptly collected for ex vivo measurement of luminescence and
viral titers. As in previous studies in immunocompetent mice
[36,37], viral titers and bioluminescence were limited to the
respiratory tract. As shown in Figure S4, in vivo bioluminescence
intensity levels in living animals were well correlated with ex vivo
luminescence (R
2 0.878) and with viral titers in the nasopharynx (R
2
0.864), trachea (R
2 0.915), and lungs (R
2 0.961). The correspon-
dence of these data validates the technique as a means of
noninvasive measurement of infection in vivo. To determine whether
the luciferase-reporter genes were genetically stable in the three
rSeVs,werecoveredlungtissuesfrom129/SvJmiceinoculatedwith
7,000 PFU of virus at 7 d p.i., homogenized the samples, and
conducted plaque assays in LLC-MK2 cells. Five plaques of each of
the three luciferase-expressing viruses were picked, amplified by one
round of replication in eggs, RT-PCR transcribed, and sequenced.
All of the individual viral clones contained the luciferase insert,
which had no amino acid mutations, and expressed luciferase when
grown in LLC-MK2 cells.
We next measured the kinetics and tropism of bioluminescence
in living 129/SvJ mice and compared the results to conventionally
Figure 1. In vitro and in vivo phenotypes of luciferase-expressing Sendai viruses. (A) Recombinant Sendai viruses that contain the firefly
luciferase gene (luc) inserted into the P-M, M-F, and F-HN gene junctions were generated. (B) Multiple-step replication kinetics of wild-type (WT) and
luciferase-expressing Sendai viruses in LLC-MK2 cell cultures infected at a multiplicity of infection (MOI) of 0.01 PFU/cell and incubated at 33uC (closed
symbols) and 37uC (open symbols). (C) Kinetics of luciferase reporter gene expression in LLC-MK2 cells infected with recombinant Sendai viruses at an
MOI of 5 PFU/cell, as measured by luminescence. (D) Changes in mean body weight after intranasal inoculation of Sendai viruses. (E) Percent survival
after intranasal inoculation of Sendai viruses. (F) Total lymphocyte counts in bronchoalveolar lavage fluid (BALF) 10 days after infection. (G) Sendai
virus-specific binding antibody titers in sera collected 10 days after infection, as measured by reciprocal endpoint dilutions in ELISA assays. For panels
D–G, groups of five 8-week-old 129/SvJ-strain mice were intranasally inoculated with 7,000 PFU of recombinant Sendai virus or phosphate buffered
saline (PBS) and the experiments were performed twice. Cumulative data are shown in panels D and E, and representative data are shown in panels F
and G.
doi:10.1371/journal.ppat.1002134.g001
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rSeV-luc(M-F*) and rSeV-luc(F-HN) had in vitro replication rates
and in vivo pathogenicity similar to those of WT virus, they also
had WT-like titers in the nasal turbinates, trachea, and lungs. In
the nasal turbinates, high virus titers (.10
5 PFU) were detected by
day 2 p.i. and were maintained until day 9 p.i., after which rapid
clearance occurred (Figure 3B). Between days 2 and 9 p.i., high
levels of in vivo bioluminescence were similarly observed in the
nasopharynx (.10
8 photons/s) of 129/SvJ mice infected with
rSeV-luc(M-F); bioluminescence peaked at about 5 d p.i.
(Figure 3A). In the lungs, the titers of all three luciferase-expressing
viruses and of WT SeV peaked by day 5 p.i. and fell to low levels
by day 9 p.i. Infection with the attenuated rSeV-luc(P-M) resulted
in peak lung titers of ,10
4 PFU (approximately 5% of the WT
titer) at day 5 p.i. (Figure 3D). Similarly low levels of rSeV-luc(P-
M) bioluminescence were observed in the lungs (Figure 3A),
consistent with the attenuated and avirulent virus phenotype. On
the other hand, rSeV-luc(P-M) reached high peak titers (,10
5
PFU, similar to the WT titer) in the nasal turbinates at 7 d p.i.
(Figure 3C), and high levels of bioluminescence were observed in
the nasopharynx between days 3 and 7 p.i. (Figure 3A).
Tissue tropism and viral dose
The high permissivity of the URT and trachea to infection by
the attenuated rSeV-luc(P-M) virus was unexpected. We next
investigated whether these tissues were also highly permissive to
infection by the WT-like virus rSeV-luc(M-F*) at a low inoculating
dose. Our preliminary studies showed that the 50% mouse
infectious dose (MID50) of rSeV-luc(M-F*) was 9 PFU and that a
70-PFU dose resulted in 100% infection, similar to results
obtained for WT SeV in mice [38] and HPIV1 in humans [39].
We inoculated 129/SvJ mice intranasally with 70, 700, or 7,000
PFU of rSeV-luc(M-F*) in equal 30 ml volumes and then measured
bioluminescence and viral titers. After inoculation with 70 PFU,
viral titers and bioluminescence in the lungs were ,10% of that
induced by a 7,000-PFU dose (Figure 4A,B), and weight loss was
far less (Figure 4C). In contrast, infection in the nasopharynx and
trachea after a 70-PFU inoculation was delayed ,1 d compared
to 7,000-PFU inoculation, reached a similar level by ,5 d p.i.
(Figure 4A,B), and induced relatively high titers of SeV-specific
antibodies (.10
5) (Figure 4D). Therefore, low-dose inoculation of
the WT-like rSeV-luc(M-F*) virus resulted in preferential infection
of the URT and trachea, inducing a robust antibody response
without causing much weight loss.
Tissue tropism and host genetics
While it is known that 129/SvJ and DBA/2 mice are highly
susceptible to lung infection by SeV and BALB/c and C57BL/6
mice are highly resistant [40–43], the effect of host genetics on
SeV replication in the URT and trachea has not been reported.
Therefore, we measured the in vivo dynamics of SeV infection in
129/SvJ, DBA/2, C57BL/6, and BALB/c strains of mice that had
been intranasally inoculated with 7,000 PFU of rSeV-luc(M-F*).
As expected from previous studies, the extent of pulmonary
infection and weight loss correlated with each other and followed
the trend C57BL/6,BALB/c,,DBA/2,129/SvJ (Figure 4). In
Figure 2. Non-invasive bioluminescence imaging of Sendai virus infection in the respiratory tracts of living mice. Eight-week-old mice
were intranasally inoculated with 7,000 PFU of rSeV-luc(P-M), rSeV-luc(F-HN), or rSeV-luc(M-F*). Every 24 hours the mice were intraperitoneally
injected with luciferin substrate, anesthetized with isoflurane, imaged with a Xenogen IVIS device, and then allowed to recover. Bioluminescence in
one experiment is shown on day 2 (A) and day 7 (B) post-infection (p.i.) in 129/SvJ mice infected with rSeV-luc(P-M), rSeV-luc(F-HN), or rSeV-luc(M-F*).
Bioluminescence in a second experiment is shown on day 2 (C) or day 7 (D) for 129/SvJ, DBA/2, BALB/c, or C57BL/6 mice infected with rSeV-luc(M-F*).
The data are displayed as radiance (bioluminescence intensity) on a rainbow log scale with a range of 1610
6 (blue) to 1610
9 (red) photons/s/cm
2/
steradian. Red circles indicate regions of interest (ROI) used to calculate the total flux (photons/s) in the nasopharynx, and red rectangles indicate the
ROI areas for the trachea and lungs.
doi:10.1371/journal.ppat.1002134.g002
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the URT and trachea in all four strains of mice. The titers of
rSeV-luc(M-F*) in BALB/c mice correlated with bioluminescence
in intact mice (Figure S5A), as they were in 129/SvJ mice.
Therefore, use of the bioluminescence technique to measure
respiratory tract infection in living mice was validated in both
129/SvJ and BALB/c strains.
Dynamics of infection during contact transmission
SeV, the HPIVs, and HRSV are thought to be transmitted
primarily via contact with respiratory secretions as opposed to
long-range transmission of these secretions as small-particle
aerosols [21,22,24,44,45]. It has also been shown that growth of
SeV [21] and influenza virus [46] in the URT promotes
transmission. Two fundamental questions about PIV transmission
that have long remained unanswered are (i) how growth of virus in
the lungs of donors influences transmission and (ii) how infection
spreads in the respiratory tracts of contact animals after
transmission. To address these fundamental questions about SeV
transmission, we inoculated BALB/c or 129/SvJ donor mice with
70 or 7,000 PFU of rSeV-luc(M-F*) and then at 1 d p.i. we placed
1 donor mouse in a ‘‘clean’’ cage with 3 naı ¨ve contact mice. We
measured bioluminescence daily in inoculated and contact mice
until primary infection was cleared. We then collected sera on day
60, challenged the mice with 7,000 PFU of rSeV-luc(M-F*) on day
63, and subsequently imaged the mice daily to detect reinfection
(Figures 5 and 6). Transmission to every naı ¨ve contact mouse was
observed by nasopharyngeal bioluminescence and seroconversion,
including resistant BALB/c mice exposed to donor animals
inoculated at the lower dose of 70 PFU (Figure 5). The timing
of transmission was not influenced by the extent of lung infection
in donors, as lung titers were ,10 times lower in BALB/c than in
129/SvJ donor mice after 7,000-PFU inoculation (Figure S5C), yet
the timing of transmission (time between detection in inoculated
animals and contact animals) was similar (3.3 and 3.4 days,
respectively) (Figure 6F). While LRT infection occurred in both
strains of mice and may have contributed to transmission, the
primary determinant of transmission appeared to be virus
shedding in the URT and trachea. For example, both high-titer
(.10
5 PFU) shedding in the nasal cavities and trachea of 129/SvJ
donor mice (Figure 4A,B) and contact transmission (Figure 6E,F)
occurred ,1 day earlier after 7,000-PFU inoculation than after
70-PFU inoculation.
Under all four conditions tested (129/SvJ or BALB/c donor
mice infected with 70 or 7,000 PFU of virus), the tropism and
magnitude of infection in contact animals was similar to that
observed after direct intranasal inoculation with 70 PFU of rSeV-
luc(M-F*). After contact transmission, bioluminescence was first
observed in the nasopharynx and then spread to the trachea and
lungs an average of 0.8 and 1.0 days later, respectively (Figure
S6A–D). Robust infection was observed in the nasopharynx and
trachea after transmission (Figure 6A–D, Figure S6E–H). In
contrast, low levels of infection in the lungs were observed after
transmission, consistent with low weight loss (Figure 6G–H). In all
four groups of mice, SeV-specific antibody titers on day 60 were
similarly high (,10
6) and all animals were protected from
challenge on day 63 (Figure 5). After challenge, a low level of
bioluminescence (,10
6 photons/s), but no weight loss, was
detected in only 1 of the 30 contact mice; this animal had shown
the lowest level of bioluminescence on days 5–12 after primary
infection (Figure 5B, solid black circles). As this animal also had
the lowest level of SeV-specific antibodies at day 60 before
challenge, a threshold level of infection may be required to induce
the highest levels of protective immunity. Overall, SeV infection
after transmission was observed to be sufficiently robust in the
URT and trachea, yet sufficiently limited in the lungs, to induce
protective immunity without causing severe pathogenesis.
Discussion
In this study, we generated and used luciferase-reporter viruses
to study the kinetics of SeV infection in living mice after direct
inoculation or contact transmission. WT SeV virus and the
Figure 3. Kinetics of Sendai virus spread and clearance in the respiratory tracts of 129/SvJ mice. (A) The extent of infection was
determined by non-invasive bioluminescence imaging of living, anesthetized mice every 24 h. Each data point represents the mean bioluminescence
of 6 mice. The total flux (photons/s) of bioluminescence intensity is calculated as the sum of radiance in the region of interest. (B–D) Viral titers in the
nasal turbinates, trachea, and lungs were determined by sacrificing groups of 3 mice at the reported days and performing plaque titrations of tissue
homogenates in LLC-MK2 cells. Both experiments were repeated, and representative data are shown.
doi:10.1371/journal.ppat.1002134.g003
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tion rate in vivo and elicited similar levels of weight loss, mortality,
bronchoalveolar lymphocyte influx, and serum antibody titers.
Both susceptible (129/SvJ) and resistant (BALB/c) strains of mice
were intranasally inoculated with 70- and 7,000-PFU doses of
rSeV-luc(M-F*), and the spread of infection was measured by both
in vivo bioluminescence in intact mice and ex vivo virus titers in the
tissues of sacrificed animals. The consequences of infection in the
URT and trachea were found to be distinct from those of infection
in the lungs. Unexpectedly, under all conditions tested, including
70-PFU inoculation of resistant BALB/c mice, the URT and
trachea supported robust SeV growth, efficient contact transmis-
sion, and protective immunity independently of the extent of
infection in the lungs. In contrast, the extent of infection in the
lungs varied with the virus dose and mouse strain and was highly
correlated with weight loss and mortality. Overall, the results
reported here reveal a tissue-specific dichotomy in the respiratory
tract in which robust infection in the URT and trachea supports
efficient transmission while the extent of infection in the lungs and
the host response determines disease severity.
Here we describe for the first time the development of a non-
invasive bioluminescence imaging system to visualize negative-
strand RNA virus infection throughout the bodies of living
animals, using the respiratory paramyxovirus SeV as a model.
The development of a non-attenuated paramyxovirus that
expresses sufficiently high levels of a reporter gene to allow
non-invasive imaging of small animals has been challenging
because of the polarized transcription mechanism of these non-
segmented negative-strand RNA viruses [2]. A significant
advance described here is the generation of the rSeV-luc(M-F*)
virus, in which the attenuating effect of reporter-gene insertion
[32] is counteracted by enhancement of the naturally occurring
but suboptimal start sequence upstream of the F gene [33].
Expression of the F gene, a virulence factor [47,48], is also
downregulated by HPIV1 [49], HPIV3 [50], PIV5 [51], measles
virus [52] and canine distemper virus (CDV) [47] by readthrough
transcription or long untranslated regions. Therefore, we predict
that other WT-like reporter paramyxoviruses that express high
levels of luciferase can be engineered by inserting the reporter
gene into the M-F junction and maintaining F gene expression
through compensating mutations. Reporter gene expression
without attenuation of SeV has also been achieved by
construction of a bicistronic gene that contains an internal
ribosome entry site [53], although it is not yet clear whether this
approach yields sufficient luciferase expression to allow non-
invasive imaging of in vivo infection.
Figure 4. Virus replication and pathogenesis as a function of virus dose and mouse strain. After intranasal inoculation of 129/SvJ mice
with 70 to 7,000 PFU of rSeV-luc(M-F*), the total flux of bioluminescence intensity (A) and viral titers (B) were measured as described in Figure 3. (C)
Percent body weight change was measured in groups of ten 129/SvJ mice after inoculation with 70 to 7,000 PFU. The experiment was performed in
duplicate; representative data are shown. (D) Sendai virus-specific binding antibody titers in sera of 129/SvJ mice collected 10 days after inoculation
with 70 to 7,000 PFU of rSeV-luc(M-F*). Titers are reported as the reciprocal endpoint dilutions in ELISA assays. Five infected and two control mice
were used in the experiment, which was performed in duplicate. Representative data are shown. (E) The total flux of bioluminescence intensity in the
nasopharynx, trachea, and lungs after 7,000-PFU intranasal inoculation of 129/SvJ, DBA/2, BALB/c, or C57BL/6-strain mice with rSeV-luc(M-F*). Values
are the mean from six animals. The experiment was performed in duplicate, and the results from a representative experiment are shown. (F) Mean
percent weight change in groups of 10 mice after infection with 7,000 PFU of rSeV-luc(M-F*). The experiment was performed in duplicate;
representative data are shown.
doi:10.1371/journal.ppat.1002134.g004
PIV Infection and Transmission in Living Mice
PLoS Pathogens | www.plospathogens.org 6 July 2011 | Volume 7 | Issue 7 | e1002134T h eu s eo ft h el u c i f e r a s er e p o r t e rg e n ei nt h ep r e s e n tw o r k
enabled the measurement of infection throughout the entire
respiratory tracts of intact animals, allowing us to measure the
spread and clearance of infection after direct inoculation or
transmission. eGFP-expressing reporter viruses have also been
used to study the dynamics of CDV infection in ferrets [54,55]
and measles virus infection in monkeys [56,57]. The eGFP
reporter gene provides the advantage of allowing the tropism of
infection to be studied at the cellular level in dissected tissues.
Moreover, eGFP-expressing viruses can also be used to quantify
and type infected cells in the peripheral blood, skin, and mouths
of living animals. eGFP-expressing HPIV3 and Sendai viruses
have been used to study the cellular tropism of PIV infection in
well differentiated, primary epithelial cultures. In the case of
HPIV3, infection was found to be restricted to ciliated epithelial
cells and to cause little cytopathology [58]. In contrast, SeV was
found to infect ciliated and non-ciliated cells, but not goblet
cells, and was observed to induce ciliostasis, cell sloughing,
apoptosis, and cellular degeneration [59]. It is unknown
whether cell-free virus or cell-associated virus is associated with
SeV transmission.
A major finding reported here is that the efficiency and timing
of SeV transmission are independent of the extent of pulmonary
infection, clinical symptoms, and host genetics. HPIV1 transmis-
sion from asymptomatic human donors has also been observed in
an experimental setting [39] and is consistent with epidemiological
observations for PIV outbreaks in general [23,24]. These
observations suggest that LRT infection and the severity of clinical
symptoms are poor predictors of transmission potential in
surveillance and infection control efforts. As in previous work
[21,38], we observed that SeV transmission coincides with high-
titer virus growth in the URT and is remarkably efficient because
of the high infectivity of the virus (e.g., the MID50 of SeV is ,10
PFU). HPIV1, HPIV3, and HRSV are similarly highly infectious
and also transmit predominantly by direct contact or indirect
exposure to nasal secretions [44,45,60–62]. In the absence of an
available prophylactic drug for uninfected individuals in high-risk
groups (e.g., premature infants and the immunocompromised), the
Figure 5. Sendai virus infection and immune response after contact transmission. Donor mice were directly inoculated with 70 PFU
(A,C,E) or 7,000 PFU (B,D,F) of rSeV-luc(M-F*) and then introduced into a cage with 3 naı ¨ve animals one day later. The total flux of bioluminescence
intensity in the nasopharyngeal cavities of individual 129/SvJ (A–B) and BALB/c (C–D) mice are shown. Serum was collected on day 60 and contact
mice were challenged with 7,000 PFU of rSeV-luc(M-F*) on day 63 to monitor for re-infection by bioluminescence. Sendai virus-specific binding
antibody titers were measured as reciprocal endpoint dilutions of sera collected on day 60 from mice co-housed with animals inoculated with 70 PFU
(E) or 7,000 PFU (F). Open bars represent mice inoculated on day 0 and solid bars represent the contact mice. The experiment was performed in
triplicate for 129/SvJ mice (3 donor and 9 contact mice) and duplicate for BALB/c mice (2 donor and 6 contact mice).
doi:10.1371/journal.ppat.1002134.g005
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should focus on reducing URT shedding from infected individuals,
disinfecting contaminated surfaces, and hand washing. In contrast
to infection control, which would be best served by limiting URT
infection, therapeutic antivirals would be better targeted to the
LRT to control clinical manifestations of PIV-associated disease.
Genetic factors have been identified that modulate viral
susceptibility and disease severity in humans [63–65] and in the
lungs of mice [40,42,43,66–70]. Our results show for the first time
that genetic factors limiting virus growth in the lungs of resistant
BALB/c mice, compared to susceptible 129/SvJ mice, do not limit
robust virus growth in the URT and trachea and, consequently, do
not limit transmission. Furthermore, BALB/c and 129/SvJ mice
showed a similarly high extent of infection in the URT and
trachea and a similarly low extent of infection in the lungs after
exposure to cagemates inoculated with high or low virus doses.
This finding shows that host genetics do not play a major role in
SeV transmission, at least in these strains of mice. These
observations reinforce our inference that transmission and
pathogenesis are independent consequences of URT versus LRT
infection, respectively. Additional experiments are needed to
delineate the mechanisms responsible for the higher permissivity of
the URT and trachea than of the lungs to SeV infection. Possible
mechanisms include the site of inoculation in the nasal cavity,
lower temperature in the URT, tissue-specific differences in virus
replication and innate immunity, and antiviral mechanisms, such
as surfactant proteins in the lungs. Reduced replication in the
lungs may be associated with lower levels of the secreted tryptase
Clara, which is required for cleavage of the F protein to allow viral
entry [71,72].
Asymptomatic infection that promotes immunity and transmis-
sion represents a balanced relationship that benefits both the virus
and the host. Such has been the case in several enzootic (clinically
unapparent) epidemics of SeV in which subclinical infections were
maintained in mouse and hamster colonies for years with no
increase in pathogenicity, causing apparent disease only occasion-
Figure 6. Timing and tissue-tropic spread of Sendai virus infection after contact transmission. The co-housing of contact mice with mice
inoculated with rSeV-luc(M-F*) is described in Figure 5. The total flux of bioluminescence intensity in individual, representative 129/SvJ (A–B) and
BALB/c (C–D) mice is shown for the nasopharynx (triangles), trachea (circles), and lungs (squares). Time to detection of bioluminescence (.6 log10
photons/s) in the nasopharynx after inoculation of donors with either 70 PFU (E) or 7,000 PFU (F) of virus. Mean percent weight change in BALB/c (G)
and 129/SvJ (H) mice. The contact transmission experiment was performed in triplicate for 129/SvJ mice and in duplicate for BALB/c mice. Open
symbols and bars represent directly inoculated mice and solid symbols and bars represent contact mice. In panels G and H, the symbol X indicates
PBS-inoculated control mice.
doi:10.1371/journal.ppat.1002134.g006
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observations are reminiscent of the low virulence yet high
transmissibility of the reverse-genetics engineered SeV described
here, which was derived from a modified Enders strain that had
been passaged in embryonated chicken eggs. Our results show that
the level of virus replication in the lungs affects neither the timing
nor the efficiency of transmission; thus, SeV replication in the
lungs may offer no selective advantage. Instead, we suggest the
following mechanism for symbiotic virus-host interplay in enzootic
epidemics of SeV: natural infection after transmission is sufficiently
limited in the lungs to avoid clinical signs of disease yet is
sufficiently robust in the nasopharynx and trachea to promote
efficient transmission and induce protective immunity.
Epizootic (clinically apparent) outbreaks of SeV have caused
morbidity and high rates of mortality in mouse colonies [75–77].
Two closely related, highly pathogenic field isolates of SeV are the
Ohita and Hamamatsu strains [78,79]. While inoculation with
only a few PFU of unpassaged Hamamatsu strain SeV results in
mortality in mice, the MLD50 of the virus was attenuated by as
much as 400-fold after 50 passages in eggs [80]. When the highly
pathogenic Ohita and Hamamatsu strains were adapted to LLC-
MK2 cells and chicken eggs, they were found to have selected for
mutations in the C protein and untranslated leader region,
respectively, which increase replication in cultured cells but
attenuate replication and pathogenesis in the lungs of mice [81–
83]. The bioluminescence imaging system described here would be
useful in determining whether the mutations that attenuate
replication in the lungs also attenuate replication in the URT
and trachea, thereby reducing transmission, or whether they
actually promote sustained transmission by supporting nasal and
tracheal shedding of virus while reducing pathogenesis in the
lungs. Such experiments may also reveal whether our observations
about the spread and transmission of the egg-adapted SeV extend
to unpassaged, highly pathogenic field isolates.
SeV is a promising Jennerian vaccine against HPIV1 [1,13],
and recombinant SeV vaccine vectors containing an envelope
gene from HRSV, HPIV3, or HPIV2 inserted into the F-HN gene
junction have been shown to elicit both B- and T-cell responses
that lead to protection from challenge in small-animal models [18–
20]. While SeV is pathogenic in mice, an ongoing clinical trial has
demonstrated SeV to be well tolerated in humans [17]. In non-
human primates, SeV has been shown to protect against HPIV1
challenge with no associated adverse events [15,84]. This result is
likely due in part to the sensitivity of SeV to human IFN-mediated
innate immunity [85]. As SeV is developed further as a vaccine
vector, the luciferase-expressing SeVs, imaging system, and
methods described here will be useful in investigating the effect
of vaccine dose, volume, and position of foreign antigen insertion
in the SeV genome on tissue-specific vector growth and the
immune response in small animal models. Of course, replacing the
luciferase reporter gene in SeV with a vaccine antigen could alter
in vivo replication of the vector. For example, three different
recombinant HPIV3 vectors expressing HPIV1 HN, HPIV2 HN,
or measles virus HA inserted into the P-M gene junction were
found to replicate to different levels in hamsters [86].
In summary, we have described the development of the non-
attenuated reporter virus rSeV-luc(M-F*), which can be used to
quantify tissue-specific SeV infection in living mice. Our results
reveal how infection by SeV spreads in individual, living animals
after direct intranasal inoculation and after transmission. Impor-
tantly, infection in the URT and trachea were found to be
associated with contact transmission while infection in the lungs
was found to be associated with pathogenesis. The imaging tools
developed here will provide a method to study the effect of viral
factors, host genetics, host age, immune status, environmental
conditions, and inoculation mode on the dynamics of infection and
transmission. For example, infection can be tracked non-invasively
in WT and knockout mice before immune responses are measured
ex vivo and then interpreted in light of the preceding infection.
Methods similar to those reported here could also be developed to
image infection by other paramyxoviruses in small-animal models.
Overall, our model system and results suggest tissue-targeted
approaches to PIV infection control and vaccine development,
while our non-invasive bioluminescence imaging technique is
expected to advance the preclinical testing of candidate vaccine
vectors and experimental therapies.
Materials and Methods
Ethics statement
All animal studies were approved by the Animal Care and Use
Committee of St. Jude Children’s Research Hospital and were
performed in compliance with relevant institutional policies, the
Association for the Accreditation of Laboratory Animal Care
guidelines, the National Institutes of Health regulations, and local,
state, and federal laws.
Cell culture
Monolayer cultures of LLC-MK2 cells were grown in
Dulbecco’s minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin, and
1% streptomycin at 37uC, 5% CO2.
Recombinant Sendai viruses
Unique NotI recognition sites were cloned into the P-M, M-F,
and F-HN intergenic junctions of an Enders-based pSeV viral
genome plasmid using cloning sites described previously [32]. The
firefly luciferase gene was amplified by PCR using the pGL3 Basic
vector (Promega) and a pair of AscI tagged primers, subcloned into
a shuttle plasmid containing a SeV intergenic junction and
flanking NotI restriction sites [32], and then subcloned into the
unique NotI site of each of the pSeV viral genome plasmids. Within
the pSeV-luc(M-F*) plasmid, the start signal upstream of the F
protein was changed from AGGGATAAAG to AGGGTGAAAG
by using the QuikChange Site-Directed Mutagenesis Kit (Strata-
gene Corp). The rSeVs were rescued from the pSeV genome
plasmids as described previously [20].
Luciferase expression in vitro
rSeV-infected LLC-MK2 cells (MOI, 5 PFU/cell) were
incubated at 33uC, 5% CO2, and lysates were collected at various
times p.i.. Luciferase assays were performed using the Luciferase
Assay System (Promega) and expression was measured on an
automated luminometer (Turner Biosystems, Inc.) as described
previously [87].
Viral titers and bioluminescence imaging
Virus titers from multistep growth curves (MOI of 0.01 PFU/
cell) and homogenized tissues were determined by plaque titration
in LLC-MK2 cells as described previously [48]. Eight week-old
female 129/SvJ mice or BALB/c mice (Jackson Laboratories) were
anesthetized with isoflurane (Baxter Health Care Corp.) and
inoculated intranasally (i.n.) with 30 ml of PBS or PBS containing
virus. Animals were monitored daily for weight loss, morbidity,
and mortality. Before imaging, mice were injected intraperitone-
ally with luciferin (Xenogen Corp) at a dose of 150 mg/kg of body
weight and anesthetized with isoflurane for 5 min. In vivo images
were acquired with a Xenogen IVIS CCD camera system (Caliper
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(Caliper Life Sciences) using an exposure of 60s, 30s, or 5s (binning
4; f/stop 1). Pseudocolor images (representative of biolumines-
cence) of mice were displayed using a binning of 4 on a




2/steradian), which is defined as the number of
photons that leave a cm
2 of tissue and radiate into a solid angle of
one steradian. To quantify bioluminescence, regions of interest
(ROI) were defined manually and graphed data were expressed as
total flux (photons/s), which is defined as the radiance within each
pixel summed over the ROI area (cm
2)64p. For experiments
shown in Figures 1D, 1E, 2, 3, 4E, 4F, and S4, mice were
anesthetized by IP injection of 300 ml 2,2,2-Tribromoethanol
(300 mg/kg) and chest hair was removed by shaving and
application of a depilatory cream 3 d before inoculation.
Immunology
Sera and BALF were collected from euthanized animals on day
10 or day 60 p.i.. BALF samples (3 ml) were centrifuged to collect
cellular material and plated in a tissue culture dish for 1 h at 37uC
to remove adherent cells. Suspension cells were harvested, total
lymphocytes were counted microscopically, and red blood cells
were lysed. For analyses by flow cytometry, cells were stained with
FITC-conjugated anti-CD4 (RM4-4) and PE-conjugated anti–
CD8b (53-5.8) antibodies (BD Biosciences Pharmingen). Lympho-
cytes were gated based on forward and side scatter, and the
percentages of CD4+ and CD8+ T cell populations were
measured within this gate. ELISAs were used to measure the
levels of SeV-specific or luciferase-specific antibodies present in the
sera. Briefly, 96-well plates were coated overnight with disrupted,
purified SeV (10 mg/ml) or firefly luciferase (1 mg/ml, Abcam).
Plates were blocked with PBS containing 1% BSA and then
incubated with 10-fold serially diluted serum samples. After
incubation, plates were washed, incubated with HRP-Goat anti
mouse IgG (Southern Biotechnologies) and then washed further.
To quantify levels of antibodies, TMB substrate (Kirkegaard and
Perry Laboratories) was added to the wells followed by stop
solution and absorbance was read at a wavelength of 450 nm.
GraphPad Prism non-linear regression software was used to
calculate antibody titers.
Contact transmission
Donor animals were inoculated intranasally with 30 mLo f
rSeV-luc(M-F*) and were individually placed into cages containing
3 naı ¨ve contact mice at 24 h p.i. Bioluminescence was monitored
daily until it remained consistently at background levels (,15
days). Sera were collected on day 60 so that SeV-specific antibody
levels could be measured as described above. On day 63, mice
were challenged with 7000 PFU rSeV-luc(M-F*) administered i.n.
and bioluminescence was measured daily.
Supporting Information
Figure S1 Construction of luciferase-expressing Sendai viruses.
(A) Nucleotide sequence of the firefly luciferase gene cassette. A
pGEM3 cloning plasmid was engineered to contain flanking NotI
restriction sites, the firefly luciferase reporter gene, gene end, and
gene start sequences. (B) To insert the luciferase reporter gene
cassette into three gene junctions, three pSeV genome plasmids
were cloned to contain a unique NotI restriction site in each of the
P-M, M-F, and F-HN gene junctions. For the pSeV-luc(M-F*)
genome plasmid, the naturally occurring suboptimal start signal
AGGGATAAAG was also mutated to the more efficient start
signal AGGGTGAAAG to compensate for expected attenuation
due to the addition of the foreign gene and additional gene
junction. The firefly luciferase gene cassette (panel A) was
subcloned from the pGEM3 plasmid into the pSeV genome
plasmids using the NotI restriction sites. (C) Design of pSeV cDNA
plasmids for the rescue of WT and recombinant Sendai viruses
containing the luciferase reporter gene (luc). The locations of the
Sendai virus genes nucleoprotein (N), polymerase (P), matrix (M),
fusion (F), hemagglutinin-neuraminidase (HN), and large (L)
protein are shown, as well as the T7 RNA polymerase promoter
(T7) and hepatitis delta virus ribozyme sequence (ribo). Gene start
sequences are shown in green and the naturally occurring,
suboptimal AGGGATAAAG gene start sequence between the
M and F genes of WT Sendai virus is shown in yellow. Gene end
sequences are shown in red. The 39 leader sequence upstream of
the N gene and the 59 trailer sequence downstream of the L gene
are not shown for simplicity.
(TIF)
Figure S2 Sendai virus protein expression and incorporation
into virions. (A) Sendai virus protein expression in LLC-MK2
cells. Confluent monolayers of LLC-MK2 cells were infected with
recombinant Sendai viruses at an MOI of 5 PFU/cell and
incubated for 16 h before radiolabeling with 50 mCi [
35S]Promix
(Amersham Pharmacia Biotech). Supernatant was incubated
overnight at 4uC with mouse anti- NP, P, M, F, and HN
monoclonal antibodies, and immune complexes were adsorbed on
protein G-Sepharose (GE Healthcare), fractionated on 12%
NuPAGE bis-Tris SDS-PAGE gels (Invitrogen), and visualized
with a phosphorimager. (B) Ratios of Sendai virus protein
expression. Protein expression was quantified with ImageQuant
5.2 software and normalized to the expression level of the N
protein. The data represent the means (+/2 standard deviation)
from three experiments. (C) Sendai virus composition. Recombi-
nant Sendai viruses were inoculated into 10-day-old embryonated
chicken eggs. Allantoic fluid was harvested 72 h p.i. and
centrifuged for 45 min at 3000 rpm to remove cellular debris.
Supernatants were layered over a 60%–20% sucrose gradient and
centrifuged at 24,000 rpm for 3.5 hrs to isolate virions. Isolated
virions were diluted in TNE buffer and further purified by
centrifugation over a 20% sucrose cushion at 24,000 rpm for 15 h.
Virus pellets were resuspended in RIPA buffer and total protein
concentrations were determined using the BCA protein assay kit
(Thermo Sci.). Equal quantities of protein were separated on a
4%–12% SDS-PAGE gel, stained with Blue BANDit protein stain
(Amresco), and dried in a BioRad gel dryer at 60uC for
45 minutes.
(TIF)
Figure S3 Immune responses of mice to infection with
recombinant Sendai viruses. Groups of five 8-week-old 129/SvJ
mice were intranasally inoculated with 30 ml containing 7,000
PFU of recombinant Sendai virus or PBS. On day 10 p.i., serum
was collected and the mice were euthanized to recover
bronchoalveolar lavage fluid (BALF). Experiments were per-
formed twice with representative data shown. Each data point
represents an individual animal and horizontal bars show group
means. The numbers of CD4+ (A) and CD8+ (B) T cells recovered
from BALF were determined by flow cytometry. (C) Luciferase-
specific binding antibody titers in sera were determined by ELISA
assays and are expressed as reciprocal endpoint dilutions. Firefly
luciferase protein (Abcam) was used.
(TIF)
Figure S4 Bioluminescence and Sendai virus titers in the
respiratory tracts of 129/SvJ mice. Groups of three 8-week-old
mice were intranasally inoculated with 7,000 PFU of recombinant
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luciferase-expressing viruses on days 4 and 6 p.i., after which lungs
were immediately harvested and homogenized so that ex vivo
luciferase activity could be measured. A fit of the data with a least
squares linear regression model yielded an R
2 value of 0.878. RLU
denotes relative light units. (B) Comparison between light detected
by the camera and viral titers of homogenates from the
nasopharynx (triangles), trachea (circles), and lungs (squares).
Each point represents data from a single mouse infected with
rSeV-luc(M-F*) and studied on day 2, 3, 5, or 7 p.i.. Least squares
linear regression yielded R
2 values of 0.864, 0.915 and 0.961 for
the nasopharynx, trachea, and lungs, respectively.
(TIF)
Figure S5 Bioluminescence and viral titers in the respiratory
tracts of BALB/c and 129/SvJ mice. Groups of three 8-week-old
mice were intranasally inoculated with either 70 or 7,000 PFU of
rSeV-luc(M-F*). (A) In vivo bioluminescence was measured in
BALB/c mice infected with 7,000 PFU of virus on days 2, 3, 5,
and 7 p.i., after which the animals were euthanized and tissues
were harvested so that virus titers from tissue homogenates could
be measured by plaque titration in LLC-MK2 cells. Correlations
between virus titers in tissue homogenates and light detected by
the camera were found with R
2 values of 0.928, 0.656, and 0.846
for the nasopharynx, trachea, and lungs, respectively. Virus titers
in homogenates from the nasopharynx (B) and lungs (C) of both
BALB/c- and 129/SvJ-strain mice infected with either 70 or 7,000
PFU of rSeV-luc(M-F*) were measured by plaque titration in
LLC-MK2 cells. The data represent the mean virus titers of six
mice (+/2 standard deviation).
(TIF)
Figure S6 Tissue-specific timing and magnitude of Sendai virus
spread in the respiratory tracts of intact mice after inoculation and
contact transmission. In each group, one BALB/c or 129/SvJ
mouse was inoculated intranasally with either 70 or 7,000 PFU of
rSeV-luc(M-F*) and three contact animals were co-housed one day
later as described in Figure 5. (A–D) Time until detection of
bioluminescence in the nasopharynx (nasop.), trachea, and lungs
(limit of detection: .6 log10 photons/s) after direct inoculation
(open bars) and after contact transmission (solid bars). (E–H)
Overall magnitude of infection after direct inoculation (open bars)
and after contact transmission (solid bars) as determined by
integration of daily measurements of total flux with respect to time
using IgorPro software (Wavemetrics). The areas under the curve
(AUC) of bioluminescence are expressed as the total amount of
photons on a log10 scale. The experiment was performed in
triplicate for 129/SvJ-strain mice (3 donor animals and 9
transmitted) and duplicate for BALB/c-strain mice (2 donor
animals and 6 transmitted).
(TIF)
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